Is transjugular insertion of a temporary pacemaker a safe and effective approach?
Kwang Jin ChunHye Bin GwagJin Kyung HwangSeung-Jung ParkYoung Keun OnJune Soo KimKyoung-Min ParkPublished in: PloS one (2020)
Temporary pacemakers (TPMs) are usually inserted in an emergency situation. However, there are few reports available regarding which route of access is best or what the most preferred approach is currently in tertiary hospitals. This study aimed to compare procedure times, complication rates, and indications for temporary pacing between the transjugular and transfemoral approaches to TPM placement. We analyzed consecutive patients who underwent TPM placement. Indications; procedure times; and rates of complications including localized infection, any bleeding, and pacing wire repositioning rates were analyzed. A total of 732 patients (361 treated via the transjugular approach and 371 treated via the transfemoral approach) were included. Complete atrioventricular block was the most common cause of TPM placement in both groups, but sick sinus syndrome was especially common in the transjugular approach group. Separately, procedure time was significantly shorter in the transjugular approach group (9.0 ± 8.0 minutes vs. 11.9 ± 9.7 minutes; P < 0.001). Overall complication rates were not significantly different between the two groups, and longer duration of temporary pacing was a risk factor for repositioning. The risk of reposition was significantly increased when the temporary pacing was continued more than 5 days and 3 days in the transjugular approach group and the transfemoral approach group, respectively. The transjugular approach should be considered if the TPM is required for more than 3 days.
Keyphrases
- transcatheter aortic valve implantation
- transcatheter aortic valve replacement
- cardiac resynchronization therapy
- end stage renal disease
- minimally invasive
- aortic valve replacement
- healthcare
- newly diagnosed
- chronic kidney disease
- emergency department
- ejection fraction
- prognostic factors
- left ventricular
- pulmonary embolism
- adverse drug